Skip to main content
OpenTrials
Completed

NCT Number: NCT05781256

Novel BP Monitoring Methods to Study the Association Between Sleep BP Patterns and BP Values in Daily Life

Out-of-office blood pressure (BP) measurement by means of ambulatory BP monitoring (ABPM) or home BP monitoring (HBPM) is recommended for the diagnosis and management of hypertension in the latest guidelines. Ambulatory BP values are more strongly associated with target organ damage and cardiovascular (CVD) events than office values. In particular, nocturnal blood pressure level and reduction of BP during the night (dipping) have been recognised as predictors of cardiovascular complications. However, in current clinical practice, these parameters are derived from ABPM. HBPM represents an inexpensive alternative to ABPM, is preferred by patients and provides a more realistic assessment of BP during an individual's daily life. However, until recently, HBPM did not offer the possibility to measure nocturnal BP or dipping.

The development and validation of new BP devices, such as the NightView (OMRON Healthcare, HEM9601T-E3) could overcome this limitation, offering the possibility of home night-time BP measurements with minimal sleep disturbance. On the other hand the use of wearable devices such as HeartGuide (OMRON Healthcare, HEM-6411T-MAE) could provide BP values in daily life conditions. Compared with conventional HBP, typically measured in resting conditions at home, values obtained with wearable devices might be closer to daytime ABP values.

Combining nocturnal HBP, with daytime BP from wearable device could therefore allow the estimation of dipping status comparable with that provided by ABPM.

In order to compare HBP-derived dipping estimate with the gold standard ABPM-derived value, it is aimed to enrol patients with hypertension, assess their blood pressure profile with ABPM and provide them with both NightView and HeartGuide devices for 7 days. Then diurnal and nocturnal BP and dipping derived from standard 24-hour ABPM will be compared and the combination of NightView/HeartGuide in order to understand whether the latter can offer a reliable assessment of 24h BP pattern.

For a better phenotypization of nocturnal BP and dipping status the following determinants of nocturnal BP and dipping status will be also investigated: sleep quality, sleep duration, the presence of sleep disorders, salt consumption, catecholamine phenotype.

This study will offer the unique opportunity to understand whether such new HBP devices can be offered in alternative to ABPM in the assessment of 24h BP profile in patients with hypertension.

Completed

Looking for future studies?

Notify Me

Key information

Age range

19 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Martino Pengo

Milan, MI, 20149, Italy

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • >18 years old
  • arterial hypertension defined as office systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg or the presence of antihypertensive treatment
  • antihypertensive treatment stable over 2 weeks preceding enrolment
  • written informed consent

Exclusion criteria

  • atrial fibrillation/flutter of frequent ectopic beats
  • pregnancy and lactation
  • terminal malignant disease, life expectancy <6 months
  • limb amputation
  • dementia

Treatment and study plan

Primary outcomes

  1. Nocturnal blood pressure fall - wearable validated device

    Time frame: 1 week

    Average nocturnal blood pressure fall, assessed through a validated wearable device over 7 days

  2. Nocturnal blood pressure fall - ABPM

    Time frame: 1 week

    Average nocturnal blood pressure fall, assessed through ABPM over 7 days

Secondary outcomes

  1. Average sleep duration

    Time frame: 1 week

    Average sleep duration in hours over 7 days, measured by simplified polysomnography

  2. Average systolic and diastolic blood pressure - wearable validated device

    Time frame: 1 week

    Average systolic and diastolic blood pressure in daily life conditions, assessed through a validated wearable device over 7 days

  3. Average systolic and diastolic blood pressure - ABPM

    Time frame: 1 week

    Average systolic and diastolic blood pressure in daily life conditions, assessed through ABPM over 7 days

  4. Leptin levels

    Time frame: At baseline

    Leptin levels at baseline

Sponsors and collaborators

Lead sponsor

Istituto Auxologico Italiano

Other

Registry information

Official study title

Study on the Association Between Sleep Blood Pressure Patterns and Blood Pressure Values in Daily Life - Usefulness of Novel BP Monitoring Methods

Acronym: CABER-NET

Important dates

Study start
2022
Primary completion
2023
Study completion
2024
First posted
Mar 23, 2023
Registry last updated
May 24, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.